TY  - JOUR
AU  - Romero-Lorca, Alicia
AU  - Novillo Villajos, Apolonia
AU  - Gaibar, María
AU  - Gilsanz, María Fuencisla
AU  - Galán, Miguel
AU  - Beltrán, Laura
AU  - Antón, Beatriz
AU  - Malón, Diego
AU  - Moreno, Amalia
AU  - Fernández-Santander, Ana
PY  - 2021
DO  - 10.2147/pgpm.s313594
SN  - 1178-7066
UR  - https://hdl.handle.net/20.500.14352/130269
T2  - Pharmacogenomics and Personalized Medicine
AB  - Purpose: Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor A. It is currently used in combination with chemotherapy to treat metastatic colorectal cancer. This therapy is not equally effective in every patient; in...
LA  - eng
M2  - 1263
PB  - Dove Press
KW  - Bevacizumab
KW  - Colorectal cancer
KW  - miRNAs
KW  - Overall survival
KW  - Paraffin-embedded biopsies
KW  - Progression free survival
TI  - miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer
TY  - journal article
VL  - 2021
ER  -